CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bora Pharmaceuticals Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bora Pharmaceuticals Co Ltd
6F, No.69, Xing'ai Road, Neihu District
Phone: +886 227901555p:+886 227901555 TAIPEI, 114  Taiwan Ticker: 64726472
Business Summary
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, General Manager Pao-Shi P.Sheng 4/16/2013 10/21/2009
Deputy General Manager, Director Shih-MinChen 4/9/2015 4/1/2013
Deputy General Manager TomCheng 8/5/2019 8/5/2019
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Proximagen Group plc 3rd Floor, 91-93 Farringdon Rd London United Kingdom
Minster Pharmaceuticals plc 56 Queen Anne Street London ENG United Kingdom
Impax Laboratories (Taiwan) Inc. No. 1, Kedong 3rd Road Jhunan Miao-LI Taiwan, Republic of China
Upsher-Smith Laboratories, Inc. 6701 Evenstad Drive Maple Grove MN United States

Business Names
Business Name
6472
Impax Laboratories (Taiwan) Inc.
Minster Pharmaceuticals plc
Proximagen Group plc
Upsher-Smith Laboratories, Inc.

General Information
Number of Employees: 91 (As of 12/31/2013)
Outstanding Shares: 101,192,128 (As of 2/19/2024)
Shareholders: 8,741
Stock Exchange: TPE
Fax Number: +886 227906595


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024